CHEMOMAB THERAPEUTICS LTD (CMMB) Stock News
NASDAQ:CMMB - Nasdaq - US16385C1045 - ADR - Currency: USD
CMMB Latest News, Press Relases and Analysis
New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis
Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
In 2024 reported positive nebokitug Phase 2 primary sclerosing cholangitis data and aligned on a clear, efficient path to potential FDA regulatory...
Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis
After End-of-Phase 2 meeting, Chemomab and FDA aligned on a clear pathway to regulatory approval—a single pivotal Phase 3 study for the treatment of PSC....
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Chemomab Therapeutics (NASDAQ:CMMB) just reported results for the second quarte...
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024
Chemomab Therapeutics just reported results for the second quarter of 2024.
Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
Chemomab management is participating in the Oppenheimer Movers in Rare Disease Summit on Dec 13, 2024 at the Westin Grand Central in NYC....
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
Oral presentation at AASLD highlights broad clinical activity of Chemomab’s CM-101 across multiple biomarkers and its disease-modifying potential in PSC...
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
Chemomab Therapeutics to Present at October 2024 Investor Conferences
Chemomab will participate in the ROTH Healthcare Opportunities Conference in NYC on Oct 9 and the Maxim Healthcare Virtual Summit on Oct 16 at 9am ET....
Chemomab Therapeutics to Present at October 2024 Investor Conferences
Chemomab Therapeutics to Present at September 2024 Investor Conferences
Chemomab will be presenting at the HC Wainwright Global Investment Conference and the HBM Biopharma Summit in September...
Chemomab Therapeutics to Present at September 2024 Investor Conferences
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Ph 2 PSC data showed safety/activity supporting advancing CM-101 to Ph 3. New financing extends cash runway to early 2026. 2 milestones on track for 1Q25....
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
Chemomab will report its second quarter 2024 financial results and provide a business update on August 21, 2024 at 7:00am ET....
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
Chemomab closed a $10 million PIPE financing that included new and existing top tier investors and extends the cash runway through the beginning of 2026...
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
Chemomab has regained full compliance with the Nasdaq minimum bid price rule...
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
Chemomab Therapeutics Announces $10 Million Private Placement
Chemomab Therapeutics Announces $10 Million Private Placement
Chemomab announced a $10 million PIPE that enables the company to extend its cash runway until early 2026, well past 2 upcoming milestones in early 2025....
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
Chemomab reported positive topline results from Ph 2 trial assessing CM-101 in PSC. Achieved safety endpoint and improved wide range of secondary...
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
New publication confirms the role of CCL24 in primary sclerosing cholangitis and the potential of CM-101 to impact PSC disease progression and severity....
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
Chemomab presents new data supporting clinical potential of CM-101 as novel treatment for PSC at EASL 2024 and Gordon Research Conference...
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company...